Skip to main content
OpenTrials
Completed

NCT Number: NCT04453085

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Loading trial locations.

About this study

Patients who have completed the Part2 of JR-171-101 study (NCT04227600) and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same doses received at Week 12 of the JR-171-101 study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have completed the Part 2 of JR-171-101 study
  • A patient from whom written informed consent can be obtained. If the patient is aged under 18 years (20 years in case of Japan) at the time of assent or willingness to participate in the study cannot be confirmed due to MPS I-related intellectual disability, informed permission from the patient's legally acceptable representative (e.g., his/her parents or guardians) need to be obtained instead of his/her consent. Even in this case, written informed consent should be obtained from the patient, wherever possible
  • Female patient or male patient whose co-partners is of child-bearing potential agree to use a medically accepted, highly effective method of contraception, such as spermatocidal gel plus condom, an intrauterine device or oral contraceptives until one month after the final administration.

Exclusion criteria

  • A patient who is unable to perform the study procedures, except for 6-minute walk test, neurocognitive testing, BVMT-R, HVLT-R, and T.O.V.A.
  • Judged by the principal investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumbar puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process
  • Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or hypersensitivity to any drugs
  • Otherwise judged by the principal investigator or subinvestigator to be ineligible to participate in the study in consideration of patient's safety

Treatment and study plan

JR-171

Drug

Intravenous (IV) infusion

Other names: lepunafusp alfa

Primary outcomes

  1. Number of participants with Adverse Events

    Time frame: 156 weeks

    Adverse events

  2. Incidence of abnormal laboratory test results

    Time frame: 156 weeks

    Hematology

  3. Incidence of abnormal laboratory test results

    Time frame: 156 weeks

    Biochemistry

  4. Incidence of abnormal laboratory test results

    Time frame: 156 weeks

    Serum iron tests

  5. Incidence of abnormal laboratory test results

    Time frame: 156 weeks

    Urinalysis

  6. Incidence of abnormal vital signs

    Time frame: 156 weeks

    Pulse rate

  7. Incidence of abnormal vital signs

    Time frame: 156 weeks

    Body temperature

  8. Incidence of abnormal vital signs

    Time frame: 156 weeks

    Blood pressure

  9. Incidence of abnormal vital signs

    Time frame: 156 weeks

    Body weight

  10. Incidence of abnormal EKG readings

    Time frame: 156 weeks

  11. Number of participants with Adverse Events

    Time frame: 156 weeks

    Anti-human-α-L-iduronidase antibodies

  12. Number of participants with Adverse Events

    Time frame: 156 weeks

    Anti-JR-171 antibodies

  13. Number of participants with Adverse Events

    Time frame: 156 weeks

    Infusion associated reaction (IAR)

Secondary outcomes

  1. Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid (CSF)

    Time frame: Weeks 26, 52, 104, 156

  2. Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid

    Time frame: Weeks 26, 52, 104, 156

  3. CSF opening pressure

    Time frame: Weeks 26, 52, 104, 156

  4. Change From Baseline in Heparan Sulfate Levels in Urinary

    Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156

  5. Change From Baseline in Dermatan Sulfate Levels in Urinary

    Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156

  6. Change From Baseline in Heparan Sulfate Levels in Serum

    Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156

  7. Change From Baseline in Dermatan Sulfate Levels in Serum

    Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156

  8. Change From Baseline in Liver Volume

    Time frame: Weeks 13, 26, 52, 78, 104, 156

  9. Change From Baseline in Spleen Volume.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

  10. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    Left ventricular posterior wall thickness

  11. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    interventricular septal thickness

  12. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    left ventricular mass index

  13. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    left ventricular ejection fraction

  14. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    left ventricular ejection fraction,

  15. Change From Baseline in Echocardiography.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

    E/A ratio

  16. Change From Baseline in 6-minute Walk Test Distance.

    Time frame: Weeks 13, 26, 52, 78, 104, 156

  17. Changes from baseline in cognitive age equivalent score of neurocognitive testing

    Time frame: Weeks 52, 104, 156

    Wechsler Intelligence Quotient (IQ) test or the Bayley scales of infant and toddler development

  18. Changes from baseline in outcome of adaptive behavioral function

    Time frame: Weeks 52, 104, 156

    Vineland adaptive behavior scales

  19. Changes from baseline in outcome of the Brief Visuospatial Memory Test-Revised

    Time frame: Weeks 13, 26, 52, 78, 104, 130, 156

  20. Changes from baseline in outcome of the Hopkins Verbal Learning Test-Revised

    Time frame: Weeks 13, 26, 52, 78, 104, 130, 156

  21. Changes from baseline in outcome of the Test of Variables of Attention

    Time frame: Weeks 13, 26, 52, 78, 104, 130, 156

  22. Changes from baseline in outcome of the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)

    Time frame: Weeks 13, 26, 52, 104 156

Sponsors and collaborators

Lead sponsor

JCR Pharmaceuticals Co., Ltd.

Industry

Registry information

Official study title

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2020
Registry last updated
Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.